drugset / Trial / NCT04634409

A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness

NCT04634409

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to measure how well monoclonal antibodies work, either alone or in combination, against the virus that causes COVID-19. Study drug(s) will be given to participants with early symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 or 24 weeks and includes at least 1 visit to the study site, with the remainder of assessments performed in the home, local clinic, or by phone.

Timeline

Start
2020-10-29
Primary completion
2021-07-27
Completion
2021-10-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Bamlanivimab Monoclonal antibody 175 mg Intravenous
Subject Bamlanivimab Monoclonal antibody 350 mg Intravenous
Subject Bamlanivimab Monoclonal antibody 700 mg Intravenous
Subject Bamlanivimab Monoclonal antibody 2800 mg Intravenous
Subject Bebtelovimab Monoclonal antibody 70 mg Intravenous
Subject Bebtelovimab Monoclonal antibody 175 mg Intravenous
Subject Bebtelovimab Monoclonal antibody 280 mg Intravenous
Subject Bebtelovimab Monoclonal antibody 560 mg Intravenous
Subject Bebtelovimab Monoclonal antibody 1400 mg Intravenous
Subject Bebtelovimab Monoclonal antibody 1750 mg Intravenous
Subject Etesevimab Monoclonal antibody 350 mg Intravenous
Subject Etesevimab Monoclonal antibody 700 mg Intravenous
Subject Etesevimab Monoclonal antibody 1400 mg Intravenous
Subject Etesevimab Monoclonal antibody 2800 mg Intravenous
Subject Sotrovimab Monoclonal antibody 500 mg Intravenous

Indications